Recursion Pharmaceuticals... (RXRX)
6.50
0.18 (2.85%)
At close: Jan 15, 2025, 1:37 PM
Cashflow (Annual)
Get detailed ratio statement breakdowns, uncovering price to free cash flow ratio, price per earnings, and much more.
| Year | FY23 | FY22 | FY21 | FY20 | FY19 |
| Net Income | -328.07M | -239.48M | -186.48M | -87.01M | -61.88M |
| Depreciation & Amortization | 24.40M | 11.76M | 8.40M | 4.44M | 2.49M |
| Stock-Based Compensation | 53.50M | 27.91M | 14.84M | 4.29M | 1.39M |
| Other Working Capital | -49.27M | 103.15M | -10.00M | 26.67M | 775.00K |
| Other Non-Cash Items | 12.64M | 11.37M | 4.10M | 282.00K | -499.00K |
| Deferred Income Tax | n/a | n/a | 827.00K | 1.76M | 1.05M |
| Change in Working Capital | -50.26M | 104.92M | -306.00K | 30.83M | 408.00K |
| Operating Cash Flow | -287.78M | -83.52M | -158.61M | -45.40M | -57.04M |
| Capital Expenditures | -11.96M | -37.36M | -39.80M | -6.74M | -3.91M |
| Acquisitions | 1.84M | n/a | 231.95M | -2.60M | n/a |
| Purchase of Investments | n/a | n/a | -301.14M | n/a | n/a |
| Sales Maturities Of Investments | 480.00K | 230.61M | 69.19M | n/a | n/a |
| Other Investing Acitivies | -597.00K | 230.31M | -231.95M | 595.00K | n/a |
| Investing Cash Flow | -10.23M | 193.25M | -271.74M | -8.74M | -3.91M |
| Debt Repayment | -766.00K | -90.00K | -12.80M | 6.32M | 705.00K |
| Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a |
| Dividend Paid | n/a | n/a | n/a | n/a | n/a |
| Other Financial Acitivies | 12.81M | 10.72M | 8.44M | 239.81M | 119.70M |
| Financial Cash Flow | 140.13M | 154.34M | 458.54M | 246.13M | 120.41M |
| Net Cash Flow | -157.69M | 263.76M | 28.18M | 192.00M | 59.46M |
| Free Cash Flow | -300.33M | -120.88M | -198.41M | -52.13M | -60.95M |